Search Results

[Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].

• Authors : Sorger C; Universitätsmedizin Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, Universität Leipzig, Philipp-Rosenthal-Str. 23, 04103, Leipzig, Deutschland. .; Simon JC

Subjects: Dermatologic Agents/Dermatologic Agents/Dermatologic Agents/*adverse effects ; Lung Diseases, Interstitial/Lung Diseases, Interstitial/Lung Diseases, Interstitial/*chemically induced ; Psoriasis/Psoriasis/Psoriasis/*drug therapy

• Source: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete [Hautarzt] 2020 Apr; Vol. 71 (4), pp. 309-312.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0372755 Publication Model: Print Cited Medium: Internet ISSN: 1432-1173

Record details

[Yoghurt-induced Lactobacillus bacteremia in a patient with Crohn's disease on therapy with ustekinumab and concomitant HIV-Infection].

• Authors : Haziri D; Klinik für Innere Medizin IV, Universitätsklinikum Jena, Jena.; Prechter F

Subjects: Lactobacillus*; Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy ; HIV Infections/HIV Infections/HIV Infections/*complications

• Source: Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2021 Apr; Vol. 59 (4), pp. 317-320. Date of Electronic Publication: 2020 Jun 22.Publisher: Karl Demeter Verlag Country of Publication: Germany NLM ID: 0033370 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Ustekinumab - Current position].

• Authors : Siegmund B; Högenauer C ...

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Ustekinumab*/Ustekinumab*/Ustekinumab*/adverse effects ; Ustekinumab*/Ustekinumab*/Ustekinumab*/pharmacology

• Source: Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2018 Sep; Vol. 56 (9), pp. 1077-1086. Date of Electronic Publication: 2018 Aug 13.Publisher: Karl Demeter Verlag Country of Publication: Germany NLM ID: 0033370 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Ustekinumab for the treatment of Crohn's disease : UNITI-IM-UNITI].

• Authors : Siegmund B; Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, 12200, Hindenburgdamm 30, Berlin, Deutschland. .; Nitschmann S

Subjects: Crohn Disease* ; Ustekinumab*; Antibodies, Monoclonal, Humanized

• Source: Der Internist [Internist (Berl)] 2017 Apr; Vol. 58 (4), pp. 424-426.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0264620 Publication Model: Print Cited Medium: Internet ISSN: 1432-1289

Record details

[Progressive renal insufficiency in a 55-year-old man with psoriasis].

• Authors : Herfurth K; Klinik für Innere Medizin III, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland.; Busch M

Subjects: Adalimumab/Adalimumab/Adalimumab/*therapeutic use ; Psoriasis/Psoriasis/Psoriasis/*drug therapy ; Renal Insufficiency/Renal Insufficiency/Renal Insufficiency/*chemically induced

• Source: Der Internist [Internist (Berl)] 2018 Nov; Vol. 59 (11), pp. 1204-1207.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0264620 Publication Model: Print Cited Medium: Internet ISSN: 1432-1289

Record details

Morbus Crohn: Ustekinumab induziert schnelle Symptomreduktion.

• Authors : Simon, Annika

• Source: Zeitschrift für Gastroenterologie; May2024, Vol. 62 Issue 5, p692-694, 3p

Record details

Medikamentös induzierte interstitielle Lungenerkrankung (DILD) unter Ustekinumab.

• Authors : Sorger, Constantin; Simon, Jan Christoph; Treudler, Regina

• Source: Der Hautarzt; Apr2020, Vol. 71 Issue 4, p309-312, 4p

Record details

Colitis ulcerosa: Ustekinumab gleich effektiv bei späten und frühen Respondern.

• Authors : Kessing, Richard

• Source: Zeitschrift für Gastroenterologie; May2024, Vol. 62 Issue 5, p688-690, 3p

Record details

Morbus Crohn: Vedolizumab vs. Ustekinumab nach Anti-TNF-Vorbehandlung.

• Authors : Simon, Annika

• Source: Zeitschrift für Gastroenterologie; Sep2023, Vol. 61 Issue 9, p1168-1170, 3p

Record details

Europäische Kommission erteilt Zulassung für SteQeyma® (CT-P43) von Celltrion – einem Biosimilar zu Stelara® (Ustekinumab) – für die Behandlung mehrerer chronisch-entzündlicher Erkrankungen

• Authors : Celltrion

• Source: Business Wire (German). 08/25/2024.

Record details